Phenylbutyrate therapy for pyruvate dehydrogenase complex deficiency and lactic acidosis

Rosa Ferriero, Giuseppe Manco, Eleonora Lamantea, Edoardo Nusco, Maria I. Ferrante, Paolo Sordino, Peter W. Stacpoole, Brendan Lee, Massimo Zeviani, Nicola Brunetti-Pierri

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Lactic acidosis is a buildup of lactic acid in the blood and tissues, which can be due to several inborn errors of metabolism as well as nongenetic conditions. Deficiency of pyruvate dehydrogenase complex (PDHC) is the most common genetic disorder leading to lactic acidosis. Phosphorylation of specific serine residues of the E1a subunit of PDHC by pyruvate dehydrogenase kinase (PDK) inactivates the enzyme, whereas dephosphorylation restores PDHC activity. We found that phenylbutyrate enhances PDHC enzymatic activity in vitro and in vivo by increasing the proportion of unphosphorylated enzyme through inhibition of PDK. Phenylbutyrate given to C57BL/6 wild-type mice results in a significant increase in PDHC enzyme activity and a reduction of phosphorylated E1a in brain, muscle, and liver compared to saline-treated mice. By means of recombinant enzymes, we showed that phenylbutyrate prevents phosphorylation of E1a through binding and inhibition of PDK, providing a molecular explanation for the effect of phenylbutyrate on PDHC activity. Phenylbutyrate increases PDHC activity in fibroblasts from PDHCdeficient patients harboring various molecular defects and corrects the morphological, locomotor, and biochemical abnormalities in the noam631 zebrafish model of PDHC deficiency. In mice, phenylbutyrate prevents systemic lactic acidosis induced by partial hepatectomy. Because phenylbutyrate is already approved for human use in other diseases, the findings of this study have the potential to be rapidly translated for treatment of patients with PDHC deficiency and other forms of primary and secondary lactic acidosis.

Original languageEnglish
Article number175ra31
JournalScience Translational Medicine
Volume5
Issue number175
DOIs
Publication statusPublished - Mar 6 2013

Fingerprint

Pyruvate Dehydrogenase Complex Deficiency Disease
Phenylbutyrates
Lactic Acidosis
Pyruvate Dehydrogenase Complex
Enzymes
Therapeutics
Phosphorylation
Inborn Errors Metabolism
Inborn Genetic Diseases
Hepatectomy
Zebrafish
Serine
Lactic Acid
Fibroblasts
Muscles

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ferriero, R., Manco, G., Lamantea, E., Nusco, E., Ferrante, M. I., Sordino, P., ... Brunetti-Pierri, N. (2013). Phenylbutyrate therapy for pyruvate dehydrogenase complex deficiency and lactic acidosis. Science Translational Medicine, 5(175), [175ra31]. https://doi.org/10.1126/scitranslmed.3004986

Phenylbutyrate therapy for pyruvate dehydrogenase complex deficiency and lactic acidosis. / Ferriero, Rosa; Manco, Giuseppe; Lamantea, Eleonora; Nusco, Edoardo; Ferrante, Maria I.; Sordino, Paolo; Stacpoole, Peter W.; Lee, Brendan; Zeviani, Massimo; Brunetti-Pierri, Nicola.

In: Science Translational Medicine, Vol. 5, No. 175, 175ra31, 06.03.2013.

Research output: Contribution to journalArticle

Ferriero, R, Manco, G, Lamantea, E, Nusco, E, Ferrante, MI, Sordino, P, Stacpoole, PW, Lee, B, Zeviani, M & Brunetti-Pierri, N 2013, 'Phenylbutyrate therapy for pyruvate dehydrogenase complex deficiency and lactic acidosis', Science Translational Medicine, vol. 5, no. 175, 175ra31. https://doi.org/10.1126/scitranslmed.3004986
Ferriero, Rosa ; Manco, Giuseppe ; Lamantea, Eleonora ; Nusco, Edoardo ; Ferrante, Maria I. ; Sordino, Paolo ; Stacpoole, Peter W. ; Lee, Brendan ; Zeviani, Massimo ; Brunetti-Pierri, Nicola. / Phenylbutyrate therapy for pyruvate dehydrogenase complex deficiency and lactic acidosis. In: Science Translational Medicine. 2013 ; Vol. 5, No. 175.
@article{74ec48a172714632b53fde5ca73cff62,
title = "Phenylbutyrate therapy for pyruvate dehydrogenase complex deficiency and lactic acidosis",
abstract = "Lactic acidosis is a buildup of lactic acid in the blood and tissues, which can be due to several inborn errors of metabolism as well as nongenetic conditions. Deficiency of pyruvate dehydrogenase complex (PDHC) is the most common genetic disorder leading to lactic acidosis. Phosphorylation of specific serine residues of the E1a subunit of PDHC by pyruvate dehydrogenase kinase (PDK) inactivates the enzyme, whereas dephosphorylation restores PDHC activity. We found that phenylbutyrate enhances PDHC enzymatic activity in vitro and in vivo by increasing the proportion of unphosphorylated enzyme through inhibition of PDK. Phenylbutyrate given to C57BL/6 wild-type mice results in a significant increase in PDHC enzyme activity and a reduction of phosphorylated E1a in brain, muscle, and liver compared to saline-treated mice. By means of recombinant enzymes, we showed that phenylbutyrate prevents phosphorylation of E1a through binding and inhibition of PDK, providing a molecular explanation for the effect of phenylbutyrate on PDHC activity. Phenylbutyrate increases PDHC activity in fibroblasts from PDHCdeficient patients harboring various molecular defects and corrects the morphological, locomotor, and biochemical abnormalities in the noam631 zebrafish model of PDHC deficiency. In mice, phenylbutyrate prevents systemic lactic acidosis induced by partial hepatectomy. Because phenylbutyrate is already approved for human use in other diseases, the findings of this study have the potential to be rapidly translated for treatment of patients with PDHC deficiency and other forms of primary and secondary lactic acidosis.",
author = "Rosa Ferriero and Giuseppe Manco and Eleonora Lamantea and Edoardo Nusco and Ferrante, {Maria I.} and Paolo Sordino and Stacpoole, {Peter W.} and Brendan Lee and Massimo Zeviani and Nicola Brunetti-Pierri",
year = "2013",
month = "3",
day = "6",
doi = "10.1126/scitranslmed.3004986",
language = "English",
volume = "5",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "175",

}

TY - JOUR

T1 - Phenylbutyrate therapy for pyruvate dehydrogenase complex deficiency and lactic acidosis

AU - Ferriero, Rosa

AU - Manco, Giuseppe

AU - Lamantea, Eleonora

AU - Nusco, Edoardo

AU - Ferrante, Maria I.

AU - Sordino, Paolo

AU - Stacpoole, Peter W.

AU - Lee, Brendan

AU - Zeviani, Massimo

AU - Brunetti-Pierri, Nicola

PY - 2013/3/6

Y1 - 2013/3/6

N2 - Lactic acidosis is a buildup of lactic acid in the blood and tissues, which can be due to several inborn errors of metabolism as well as nongenetic conditions. Deficiency of pyruvate dehydrogenase complex (PDHC) is the most common genetic disorder leading to lactic acidosis. Phosphorylation of specific serine residues of the E1a subunit of PDHC by pyruvate dehydrogenase kinase (PDK) inactivates the enzyme, whereas dephosphorylation restores PDHC activity. We found that phenylbutyrate enhances PDHC enzymatic activity in vitro and in vivo by increasing the proportion of unphosphorylated enzyme through inhibition of PDK. Phenylbutyrate given to C57BL/6 wild-type mice results in a significant increase in PDHC enzyme activity and a reduction of phosphorylated E1a in brain, muscle, and liver compared to saline-treated mice. By means of recombinant enzymes, we showed that phenylbutyrate prevents phosphorylation of E1a through binding and inhibition of PDK, providing a molecular explanation for the effect of phenylbutyrate on PDHC activity. Phenylbutyrate increases PDHC activity in fibroblasts from PDHCdeficient patients harboring various molecular defects and corrects the morphological, locomotor, and biochemical abnormalities in the noam631 zebrafish model of PDHC deficiency. In mice, phenylbutyrate prevents systemic lactic acidosis induced by partial hepatectomy. Because phenylbutyrate is already approved for human use in other diseases, the findings of this study have the potential to be rapidly translated for treatment of patients with PDHC deficiency and other forms of primary and secondary lactic acidosis.

AB - Lactic acidosis is a buildup of lactic acid in the blood and tissues, which can be due to several inborn errors of metabolism as well as nongenetic conditions. Deficiency of pyruvate dehydrogenase complex (PDHC) is the most common genetic disorder leading to lactic acidosis. Phosphorylation of specific serine residues of the E1a subunit of PDHC by pyruvate dehydrogenase kinase (PDK) inactivates the enzyme, whereas dephosphorylation restores PDHC activity. We found that phenylbutyrate enhances PDHC enzymatic activity in vitro and in vivo by increasing the proportion of unphosphorylated enzyme through inhibition of PDK. Phenylbutyrate given to C57BL/6 wild-type mice results in a significant increase in PDHC enzyme activity and a reduction of phosphorylated E1a in brain, muscle, and liver compared to saline-treated mice. By means of recombinant enzymes, we showed that phenylbutyrate prevents phosphorylation of E1a through binding and inhibition of PDK, providing a molecular explanation for the effect of phenylbutyrate on PDHC activity. Phenylbutyrate increases PDHC activity in fibroblasts from PDHCdeficient patients harboring various molecular defects and corrects the morphological, locomotor, and biochemical abnormalities in the noam631 zebrafish model of PDHC deficiency. In mice, phenylbutyrate prevents systemic lactic acidosis induced by partial hepatectomy. Because phenylbutyrate is already approved for human use in other diseases, the findings of this study have the potential to be rapidly translated for treatment of patients with PDHC deficiency and other forms of primary and secondary lactic acidosis.

UR - http://www.scopus.com/inward/record.url?scp=84875126013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875126013&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3004986

DO - 10.1126/scitranslmed.3004986

M3 - Article

C2 - 23467562

AN - SCOPUS:84875126013

VL - 5

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 175

M1 - 175ra31

ER -